Literature DB >> 17033215

Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.

E Ioachim1, M Michael, M Salmas, M M Michael, N E Stavropoulos, V Malamou-Mitsi.   

Abstract

Hypoxia-inducible factors (HIF-1alpha and HIF-2alpha) are closely related protein complexes that activate transcription of target genes in response to hypoxia. The immunohistochemical expression of these two proteins was investigated in 144 bladder cancer tissue samples and correlated with standard clinicopathological features, in order to elucidate their prognostic significance. We also evaluated their possible associations with other angiogenesis related markers such as microvessel density (MVD), vascular endothelial growth factor, thymidine phosphorylase, tenascin, fibronectin, p53 and bcl-2 to further clarify their implication in tumor stroma vascularization. Nuclear HIF-1alpha expression in tumor cells was detected in 57.1% of the cases. A trend of correlation of this expression with poorly differentiated tumors was observed. In addition, HIF-1alpha expression was positively correlated with stromal cells thymidine phosphorylase expression. Tumors that were progressed in muscle-infiltrating disease showed a higher HIF-1alpha expression. A higher HIF-1alpha expression was also observed in tumors with an in situ component. In tumor cells, low HIF-2alpha expression was observed in 6.3%, moderate in 31.9% and high in 61.8% of the cases. A trend of correlation of this expression with MVD was observed. In addition, HIF-2alpha expression was positively correlated with thymidine phosphorylase and fibronectin expression. A lower HIF-2alpha expression was detected in tumors that recurred earlier in univariate methods of analysis. HIF-2alpha was expressed in tumor stroma associated cells in 53.5% of specimens and was correlated with advance tumor stage, thymidine phosphorylase and tenascin expression. There was no statistically significant difference in the expression of both HIF-1alpha and HIF-2alpha between primary and recurrent tumors. In multivariate analysis including T stage, T grade, multifocality and T size, both HIF-1alpha and HIF-2alpha expression were not considered dependent in the prediction of recurrence or progression. In conclusion, the results of the present study indicate that HIF-1alpha and HIF-2alpha expression may help to predict recurrence or progression to muscle invasive disease but not as independent prognostic factors. In addition, the expression of HIF-1alpha and HIF-2alpha, appear to play a role in bladder cancer, vascularization possibly and in cooperation with other angiogenic factors. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033215     DOI: 10.1159/000094819

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  14 in total

Review 1.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 2.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

3.  Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.

Authors:  Luciana Schultz; Roula Albadine; Jessica Hicks; Sana Jadallah; Angelo M DeMarzo; Ying-Bei Chen; Matthew E Nielsen; Matthew E Neilsen; Mark L Gonzalgo; David Sidransky; Mark Schoenberg; George J Netto
Journal:  Cancer       Date:  2010-10-11       Impact factor: 6.860

4.  Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma.

Authors:  Francisco Ayala de la Peña; Keizo Kanasaki; Megumi Kanasaki; Neelima Tangirala; Genta Maeda; Raghu Kalluri
Journal:  J Biol Chem       Date:  2011-03-09       Impact factor: 5.157

5.  Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia.

Authors:  Meng-Chuan Chen; Wen-Lin Hsu; Pai-An Hwang; Tz-Chong Chou
Journal:  Mar Drugs       Date:  2015-07-17       Impact factor: 5.118

6.  Preliminary Analysis of the Expression of Selected Proangiogenic and Antioxidant Genes and MicroRNAs in Patients with Non-Muscle-Invasive Bladder Cancer.

Authors:  Magdalena Kozakowska; Barbara Dobrowolska-Glazar; Krzysztof Okoń; Alicja Józkowicz; Zygmunt Dobrowolski; Józef Dulak
Journal:  J Clin Med       Date:  2016-02-25       Impact factor: 4.241

7.  Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis.

Authors:  Eloy Moreno Roig; Ala Yaromina; Ruud Houben; Arjan J Groot; Ludwig Dubois; Marc Vooijs
Journal:  Front Oncol       Date:  2018-06-11       Impact factor: 6.244

Review 8.  Interfering with Tumor Hypoxia for Radiotherapy Optimization.

Authors:  Irma Telarovic; Roland H Wenger; Martin Pruschy
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21

9.  Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.

Authors:  C Blick; A Ramachandran; S Wigfield; R McCormick; A Jubb; F M Buffa; H Turley; M A Knowles; D Cranston; J Catto; A L Harris
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

10.  CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer.

Authors:  Makito Miyake; Shunta Hori; Yosuke Morizawa; Yoshihiro Tatsumi; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Nobumichi Tanaka; Keiji Shimada; Noboru Konishi; Michihiro Toritsuka; Toshifumi Kishimoto; Charles J Rosser; Kiyohide Fujimoto
Journal:  Neoplasia       Date:  2016-09-28       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.